Back to top

Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress

In a report released yesterday, Faisal Khurshid from Jefferies upgraded BeOne Medicines to a Buy, with a price target of $380.00. Faisal Khurshid h...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)